Allain Y M, Bolla M, Douchez J, Gary-Bobo J, Geslin J, Huart J, Mathieu G, Mazeron J J
Bull Cancer. 1985;72(6):559-67.
From 1975 to 1982, 597 patients with localized prostatic adenocarcinoma were treated using external beam irradiation in one of 6 cooperating centers. The mean patient age was 67 years. The 5 and 10 years actuarial survivals (including all causes of death) were 70% and 40% respectively. The adjusted survival rates become 86% at 5 years and 61% at 10 years when only death due to cancer is taken into consideration. Despite the fact that patients with stage A1 and A2 disease show different patterns of lymphatic spread, the actuarial and adjusted 8 years survivals were identical for both staging groups, in this study, 57% and 90%, respectively. It is significant that the majority of patients in both group A1 and in group A2 received irradiation to the pelvic lymph nodes as well as the prostate. Patients with stage B1 disease showed a 7 years actuarial survival of 53% and an 82% survival adjusted for death due to cancer only. Patients in both group B2 and group C, showed an identical 10 year actuarial survival rate of 49%. However, without CT scanning, it is difficult to differentiate between these 2 staging groups. Patients with stage C2 disease showed 10 years actuarial and adjusted survival rates of 20% and 40% respectively. The local recurrence rate after primary radiation therapy did not exceed 11% in any patient group. These data demonstrate, once again, that the dogma pertaining to the radioresistance of prostatic cancer is outdated.
1975年至1982年期间，6个合作中心之一对597例局限性前列腺腺癌患者采用外照射治疗。患者平均年龄为67岁。5年和10年的精算生存率（包括所有死亡原因）分别为70%和40%。仅考虑因癌症死亡时，调整后的5年生存率为86%，10年生存率为61%。尽管A1期和A2期疾病患者的淋巴转移模式不同，但在本研究中，两个分期组的精算和调整后的8年生存率相同，分别为57%和90%。值得注意的是，A1组和A2组的大多数患者都接受了盆腔淋巴结以及前列腺的照射。B1期疾病患者的7年精算生存率为53%，仅针对因癌症死亡调整后的生存率为82%。B2组和C组患者的10年精算生存率均为49%。然而，在没有CT扫描的情况下，很难区分这两个分期组。C2期疾病患者的10年精算生存率和调整后的生存率分别为20%和40%。在任何患者组中，原发放疗后的局部复发率均未超过11%。这些数据再次表明，有关前列腺癌放射抵抗的教条已经过时。
